Institute for Wealth Management’s Travere Therapeutics TVTX Stock Holding History

Institute for Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.8K	Buy	+67	New	+$2.97K	﹤0.01%	1499

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Institute for Wealth Management's TVTX Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 67 shares worth $3.8K. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings.

121 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Institute for Wealth Management held 67 shares of Travere Therapeutics worth $3.8K as of Q2 2026.
Travere Therapeutics was a new Institute for Wealth Management position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1499 holding.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.